Defective production of monocyte-activating cytokines in lepromatous leprosy by unknown
DEFECTIVE  PRODUCTION  OF  MONOCYTE-ACTIVATING 
CYTOKINES  IN  LEPROMATOUS  LEPROSY 
BY MARCUS  A.  HORWITZ,  WILLIAM  R.  LEVIS,  AND  ZANVIL A. COHN 
From the Laboratory of Cellular Physiology and hnmunology, The Rockefeller University, 
New York 10021 
Leprosy is a  chronic inflammatory disease caused by an obligate intracellular 
bacterial  pathogen,  Mycobacterium  leprae,  that  multiplies  within  mononuclear 
phagocytes. The disease exhibits a broad clinical spectrum (1) reflecting grada- 
tions in patient capacity to develop a specific cell-mediated immune response. In 
lepromatous leprosy, patients  fail  to mount an effective cell-mediated immune 
response and they are anergic to M.  leprae antigens.  The disease is widespread, 
and  infiltrates  are poorly organized and contain  extraordinarily  high  numbers 
of leprosy bacilli in foamy macrophages.  In tuberculoid leprosy, patients mount 
a vigorous cell-mediated immune response, and they exhibit cutaneous delayed- 
type hypersensitivity to M.  leprae antigens.  In this form, the disease is localized, 
and well-organized granulomatous infiltrates are found that contain few bacilli. 
The  immunological  defect underlying  the  lack of an  effective cell-mediated 
immune  response  in  lepromatous  leprosy  is  not  understood.  The  failure  of 
macrophages to control the intracellular multiplication of leprosy bacilli may be 
secondary to an  inability of these  macrophages  to be activated or to a  lack of 
necessary cytokines. The latter possibility is suggested by the failure of lympho- 
cytes from  patients  with  lepromatous  leprosy to proliferate  in  response  to M. 
leprae  antigens  (2-7).  The  defect  is  essentially  specific  to M.  leprae  antigens. 
Patients  with  lepromatous  leprosy commonly display cutaneous  delayed-typed 
hypersensitivity (2, 8-10) as well as, in vitro, a lymphocyte blastogenic response 
to antigens other than M.  leprae (2-6), although  sometimes responses to one or 
another antigen are impaired to varying degrees (2, 3, 7, 9-I 1). 
In  this  paper,  we studied  the  monocytes and  mononuclear  cells of patients 
with  lepromatous  and  tuberculoid leprosy to  learn  about the  capacity of their 
monocytes to undergo activation and the capacity of their mononuclear (lymph- 
oid) cells to produce cytokines able to activate monocytes. We assayed monocyte 
activation  by measuring  the  capacity of monocytes to  inhibit  the  intracellular 
multiplication  of Legionella pneumophila,  the agent of Legionnaires'  disease (12- 
13).  This  assay is  highly  relevant  to  leprosy since  the  agent  of Legionnaires' 
disease, like the agent of leprosy, is an intracellular bacterial pathogen for human 
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mononuclear phagocytes (14,  15). 
We found that  monocytes from patients with either form of leprosy undergo 
activation in response to lymphokines and strongly inhibit L. pneumophila  multi- 
plication.  However, specifically in  response to M.  leprae antigens,  mononuclear 
cells from patients with  lepromatous leprosy fail to release monocyte-activating 
cytokines. In contrast,  mononuclear cells from patients with tuberculoid leprosy 
secrete  such  cytokines,  which  activate  monocytes  to  inhibit  the  intracellular 
multiplication of L. pneumophila. 
Materials and  Methods 
Patients.  All patients were adults and were seen at the Rockefeller University Hospital 
(Table I). The diagnosis of leprosy was supported in all cases by a skin biopsy examined 
by pathologists at the  U.  S.  Public  Health Service  National  Hansen's Disease Center, 
Carville, LA. Clinical diagnosis was based on the Ridley-Jopling classification scheme (1). 
Informed written consent was obtained from all patients. 
Media.  Egg yolk buffer, with or without  1% bovine serum albumin, and RPMI  1640 
medium were prepared or obtained as described previously (10).  No antibiotics were 
added to any medium in any of the experiments. 
Reagents.  Concanavalin  A  (Con  A),  three  times  crystallized and  lyophilized (Miles- 
Yeda Ltd., Kankakee, IL); [3H]thymidine (Schwarz/Mann Division, Becton, Dickinson & 
Co., Orangeburg, NY). 
Aga r.  Modified charcoal yeast extract agar was prepared in 100 ×  15-mm bacteriologic 
petri dishes as described (14). 
Serum.  Venous blood was obtained, clotted, and serum separated and stored at -70°C 
until  used  as  described  (16).  Normal  (nonimmune)  human  serum  (type  AB)  with  an 
indirect fluorescent antibody (IFA) anti-L, pneumophila titer (17) of <1:64 was obtained 
from an adult donor not known to have ever had Legionnaires' disease. 
Bacteria.  L. pneumophila, Philadelphia  1 strain, was grown in embryonated hens' eggs, 
harvested, tested for viability and for the presence of contaminating bacteria, stored at 
-70°C, and partially purified by differential centrifugation just before use, as described 
(14). 
Human Blood Mononuclear Cells.  Heparinized venous blood was obtained from patients 
and the blood mononuclear cell fraction was separated by centrifugation over a  Ficoll- 
sodium diatrizoate solution as previously described (14). 
Preparation of Mononuclear Celt Supernatants.  A  single large batch of Con A-induced 
mononuclear cell supernatant (Con A  supernatant) and of supernatant control (Con A 
supernatant control) was prepared from the mononuclear cells of a single normal donor 
who did not have leprosy (13).  Con  A  supernatant  was prepared by incubating  donor 
mononuclear cells  6  (3  x  10/ml)  in  2  ml  RPMI  medium containing  25%  fresh normal 
human serum in plastic petri dishes with  15 #g/ml Con A for 2 d at 37°C in 5% CO2- 
95% air. This concentration of Con A and this incubation period yield a maximally potent 
Con A supernatant (12).  At the end of the incubation, the cultures were transferred to 
conical tubes and the cells were sedimented at 200 g for 10 min at 4°C. The supernatant 
was removed, filtered through 0.2 #m Millipore filters (Millipore Corp. Bedford,  MA), 
and stored at -70°C.  Con A supernatant control was prepared in the same way except 
that  Con  A  was added  at the  end  rather  than at the beginning of the  2-d incubation 
period. 
Con A supernatants and supernatant controls were prepared from patients with leprosy 
in the same way except that cells were cultured in 16-mm tissue culture wells (Linbro, 24- 
well plates; Flow Laboratories, Inc., McLean, VA) containing 500 #1 of medium; cell and 
reagent concentrations were the same as in the above paragraph. 
M. leprae supernatants were prepared from patients in the same way and at the same 
time as Con A  supernatants except that  100 ttl of partially purified, armadillo-derived, 
freeze-dried M.  leprae was used instead of Con A, and mononuclear cells were cultured 668  DEFECTIVE  CYTOKINE  PRODUCTION  IN  LEPROMATOUS  LEPROSY 
TABLE  I 
Data on Patients with Leprosy 
Patient 
Age  Sex  National  Type of  Duration of  Antibiotic therapy 
(years)  origin  leprosy*  leprosy  Drug  Duration 
A 
B 
44  M  Italy*  LL  11 yr  Dapsone  8 mo 
Rifampin  8 mo 
41  M  Puerto Rico  BT  9 yr  Dapsone  5 yr 
Rifampin  1 yr 
C  36  F  Antigua  BL  3 yr 
Dapsone  3 yr 
Rifampin  3 yr 
Clofazimine  3 mo 
D  35  M  Nigeria  BT  5 yr  Dapsone  5 yr 
E  41  F  Puerto Rico  LL  7 yr  Dapsone  5 yr 
Rifampin  5 yr 
F  45  M  China  LL  28 yr  Dapsone  14 yr 
Rifampin  6 yr 
G  48  F  Puerto Rico  TT  2 yr  None 
H  55  F  Cambodia  BT  3 mo  None 
I  53  M  Trinidad  LL  35 yr  Dapsone 
Rifampin 
25 yr 
2 yr 
J  23  M  Guyana  BL  6 mo  Dapsone  3 wk 
Rifampin  3 wk 
None 
Dapsone  3 yr 
Rifampin  3 yr 
Dapsone  3 yr 
Rifampin  2 yr 
Clofazimine  6 mo 
K  36  M  Haiti  TT  6 mo 
L  57  F  Dominican  BT  3 yr 
Republic 
M  31  F  Equador  LL  3 yr 
N  25  M  Vietnam  BT  2 yr  Dapsone  2 yr 
Rifampin  4 mo 
* Based  on  Ridley-Jopling classification:  LL,  lepromatous  leprosy;  BL,  borderline  lepromatous 
leprosy; BT, borderline tuberculoid leprosy; TT, tuberculoid leprosy. Two patients (C and M) had 
erythema nodosum leprosum at the time of the study. One patient (C) was on steroids at the time 
of the study. None of the patients were lymphopenic at the time of the study. 
* Lived in endemic area (Brazil)  prior to illness. 
with  the M.  leprae  antigen  for  5  d  instead  of 2  d. M.  leprae  supernatant  controls  were 
prepared  in the same way except that M. leprae antigen was added at the end rather than 
at the beginning of the 5-d incubation period. In another study (13), patient mononuclear 
cell responses to this M, leprae antigen were shown to be relatively specific in both of the 
assays used in this study. In both the mononuclear cell thymidine incorporation assay and 
the assay  for monocyte-activating cytokines,  mononuclear  cells from patients  recovered 
from  Legionnaires' disease  responded  more  strongly to L. pneumophila antigens  than  to HORWITZ,  LEVIS,  AND  COHN  669 
M.  leprae antigens  whereas  mononuclear  cells  from patients  with  tuberculoid  leprosy 
responded more strongly to M. leprae than to L. pneumophila  antigens (13).  The M. leprae 
antigen  was  kindly  provided  by the  Immunology of Leprosy Unit  (IMMLEP),  World 
Health Organization, Geneva, Switzerland. 
The sediments remaining after the  removal of supernatants  were all  tested  for the 
presence of contaminating microorganisms by resuspending them in RPMI medium and 
culturing aliquots of the suspension on 5% sheep blood tryptic soy broth agar; none of 
the preparations used in this study were contaminated. 
Activation of Patient Monocytes.  Patient monocytes were tested for their capacity to be 
activated by Con A-induced cytokines generated by normal mononuclear cells. Activation 
was assayed by measuring the capacity of the cytokine-treated monocytes to inhibit the 
intracellular multiplication of L. pneumophila  (12,  13).  Freshly explanted patient mono- 
nuclear cells (1.5  ×  106) were incubated in  16-mm tissue culture wells  in 500 #1 RPMI 
1640 medium containing 10% fresh normal human serum for 1.5 h at 37°C in 5% CO2- 
95% air to allow monocytes to adhere. The culture wells were then vigorously washed to 
remove the nonadherent leukocytes. The monocyte monolayers were then incubated for 
24 h  in  500  #1  RPMI medium containing  20%  fresh serum and  30%  (vol/vol) Con  A 
supernatant or supernatant control prepared as described above. After 24 h, virulent egg 
yolk-grown L. pneumophila  (5  ×  10~colony-forming units (CFU)/ml) were added to the 
cultures. The cultures were incubated at 37°C in 5% CO2-95% air on a gyratory shaker 
for 1 h and under stationary conditions thereafter. CFU of L. pneumophila in each culture 
were determined daily on charcoal yeast extract agar as described (14).  All cultures were 
prepared and tested in triplicate. 
Activation  of  Normal  Monocytes  by  Supernatants  Derived  from  Patients  with  Lep- 
rosy.  Mononuclear  cells  from a  single adult  donor  were  used in  all  experiments;  the 
donor had no history of Legionnaires' disease and had a serum IFA anti-L, pneumophila 
titer of <1:64.  Monocyte monolayers were prepared in  16-mm tissue  culture  wells  as 
described in the previous assay and incubated for 24 h  in  500 ~i  RPMI  1640  medium 
containing 20% fresh normal human serum and 30% (vol/vol) Con A supernatant, Con 
A supernatant control, M. leprae supernatant, or M. leprae supernatant control generated 
from the mononuclear cells of patients, as described above. After 24 h, the cultures were 
infected with L. pneumophila  and cultured daily for CFU/ml as described in the previous 
assay. All cultures were prepared and tested in duplicate. All supernatants from a given 
patient were tested at the same time. Two patients with lepromatous leprosy were tested 
at the same time as two patients with tuberculoid leprosy. 
Thymidine Incorporation by Mononuclear  Cells.  The mononuclear cells remaining after 
the generation of Con A  or M.  leprae supernatants or supernatant controls were resus- 
7  pended in 600 #1 RPMI medium (~1  ×  10  of the originally cultured mononuclear cells/ 
ml) as  described  (13).  Triplicate  50-IA aliquots  of this  cell  suspension  were  added  to 
microtest wells  (Falcon,  96-well tissue culture plate; Becton,  Dickinson & Co.,  Oxnard, 
CA) and mixed with an equal volume of RPMI containing 2% serum and 5.0 #Ci [SH]- 
thymidine/ml. The cells were incubated for 2 h at 37°C in 5% CO2-95% air, and harvested 
on glass fiber filter paper (Whatman, Inc., Clifton, NJ) with a cell harvester. The filters 
were dried, placed in glass vials containing liquid scintillation-counting solution (Hydro- 
fluor; National Diagnostics, Inc., Somerville, NJ), incubated overnight at 4°C, and counts 
per minute registered with a liquid scintillation counter (Nuclear Chicago Corp., Subsid- 
iary of G. D. Searle and Co., Des Plaines, IL). 
Statistics.  Data were analyzed by the two sample t test, two-tailed (18). 
Results 
Monocytes from  Patients  with  Lepromatous  and  Tuberculoid  Leprosy  Can  Both  Be 
Activated to an Enhanced Antimicrobial State.  We first examined the activation of 
monocytes from patients with  lepromatous or tuberculoid  leprosy, as measured 
by the capacity of their monocytes to inhibit  the  intracellular  multiplication  of 
L. pneumophila.  Monocytes of patients with either form of leprosy were activated 670  DEFECTIVE  CYTOKINE  PRODUCTION  IN  LEPROMATOUS  LEPROSY 
by  Con  A  supernatant  (Fig.  1  and  Table  II)  and  they strongly  inhibited  L. 
pneumophila  multiplication in comparison to monocytes pretreated with Con A 
supernatant control. The degree of inhibition was comparable in both groups. 
L. pneumophila  multiplication was decreased by a mean of 2.03 logs by activated 
monocytes from patients with lepromatous leprosy and by a  mean of 1.81  logs 
by activated monocytes from patients with tuberculoid leprosy (Table II) (differ- 
ence not  significant).  The  degree of inhibition  by activated  monocytes from 
either group of patients was not significantly different from that of activated 
monocytes from normal persons (mean 2.04 logs; Table II). 
Mononuclear Cells  from Patients with Lepromatous Leprosy Fail to Incorporate [3H]- 
thymidine Avidly in Response to M.  leprae.  We assayed the mononuclear cells of 
patients  with  both  forms  of leprosy  for  their  capacity  to  incorporate  [SH]- 
thymidine in response to M. leprae antigens. To determine the optimal concen- 
tration of M.  leprae antigens, we incubated mononuclear cells of two patients 
with tuberculoid leprosy for 5 d  with M.  leprae at concentrations ranging from 
10 to 250 #g/ml (Fig. 2). The mononuclear cells incorporated [SH]thymidine in 
response to M. leprae and the amount of incorporation was proportional to the 
concentration of M.  leprae.  Maximal or near maximal responses were obtained 
with 50-100 pg/ml M. leprae. In all subsequent studies, we used M. leprae antigens 
at a concentration of 100 pg/ml. 
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FICURE  1.  Activated monocytes from patients with leprosy inhibit L. pneumophila multipli- 
cation.  Monocyte monolayers were prepared in tissue culture wells  from freshly explanted 
mononuclear cells of patient A, as described in Materials and Methods. The monocytes were 
incubated for 24  h  with 30%  Con A-induced supernatant or supernatant control prepared 
from the mononuclear cells of a normal person. The monocytes were then infected with L. 
pneumophila (2.5  ×  10 s CFU/ml) and CFU/ml was determined daily. Each point represents 
the mean CFU/ml for three replicate tissue culture wells +  SEM. HORWITZ,  LEVIS,  AND  COHN  671 
TABLE  II 
CFU of L. pneumophila at Peak of Infection in Monocyte Cultures Preincubated with Con A 
Supernatant or Supernatant Control 
Leprosy type 
Lepromatous 
Patient  Supernatant control  Supernatant  Log inhibition* 
CFU/ml 
A  1.7 + 0.03 ×  106  2.8 -  0.6 ×  l0  s  2.78 
C  9.1± 1.5  ×  104  1.4±0.3x  l0  s  1.81 
E  2.5_+0.3  ×  106  3.8±0.3×  104  1.82 
F  8.1±2.7  ×  104  2.8 _-4-  0.3×10 s  1.46 
I  1.5±0.8  X  104  4.7 --4-].8× 10 ~  1.51 
J  4.5_0.5  ×  105  6.7±2.2×  10  ~  2.82 
Mean 2.03 + 0.35* 
Tuberculoid  B  3.9  +  0.8  x  105  6.8 + 0.9 x  105  1.76 
D  1.6 + 0.2 ×  105  3.1 _  0.4 x  10  s  1.71 
G  9.8 ± 5.2 ×  104  4.7 _  2.5 x  l0  s  1.32 
H  4.8 +  1.5 x  104  3.2 _  1.6 x  102  2.25 
K  1.2 ± 0.1 x  106  5.8 -  0.9 x  l0  s  2.32 
L  2.7 + 0.4 x  10  ~  8.8 ± 0.9 x  l0  s  1.49 
Mean 1.81 _+ 0.23* 
Monocyte monolayers were prepared in tissue culture wells from freshly exptanted mononuclear 
cells of patients A-L, incubated for 24 h with 30% Con A supernatant or supernatant control, and 
infected with L. pneumophila as in Fig. 1. CFU/ml were determined daily. Data presented are CFU/ 
ml at the peak of infection, i.e., when CFU/ml in control cultures reached their highest level (2 or 
3 d after infection). Data are the mean CFU/ml for three replicate tissue culture wells _  SEM. 
Monocytes from three normal persons activated by the same batch of Con A supernatant used 
throughout this study inhibited L. pneumophila multiplication by a mean of 2.04 + 0.40 logs. This 
degree of inhibition was not significantly different from that of activated monocytes from either 
group of patients. 
* Log inhibition = (log CFU/ml in monocyte cultures treated with supernatant control) -  (log CFU/ 
ml in monocyte cultures treated with supernatant). 
*P> 0.5. 
We next studied [~H]thymidine incorporation in response to M. leprae antigens 
and Con A  of mononuclear  cells from patients with lepromatous and tuberculoid 
leprosy (Table III). Mononuclear  cells from both types of patients showed strong 
[3H]thymidine  incorporation  in  response  to  Con  A.  Mononuclear  cells  from 
patients with  tuberculoid  leprosy also showed  strong  [3H]thymidine  incorpora- 
tion  in  response  to M.  leprae  antigens.  In  contrast,  patients  with  lepromatous 
leprosy  showed  weak  [SH]thymidine  incorporation  in  response  to  M.  leprae 
antigens. Similar results have been reported  by others (2-7). 
Mononuclear Cells  from Patients with Lepromatous Leprosy Fail to Generate Monocyte- 
activating Cytokines in Response to M. leprae.  We assayed the mononuclear  cells of 
patients with lepromatous and tuberculoid leprosy for their capacity to generate 
monocyte-activating cytokines in  response  to Con  A  and M.  leprae.  To  do this, 
we prepared  Con  A  and M.  leprae supernatants  and  supernatant  controls from 
the  mononuclear  cells  of patients  with  leprosy  as  described  in  Materials  and 
Methods. We then tested the capacity of these preparations to activate monocytes 
by treating normal  monocytes  with  each  preparation  and  measuring  monocyte 
capacity to inhibit the  intracellular multiplication of L. pneumophila  (Table IV). 
The various supernatant preparations were obtained from the same mononuclear 672  DEFECTIVE CYTOKINE  PRODUCTION  IN  LEPROMATOUS  LEPROSY 
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FIGURE 2.  [3H]thymidine  incorporation by mononuclear cells from patients with tuberculoid 
leprosy in response to M. leprae. Mononuclear cells (3 x  10~]ml) were incubated in tissue 
culture wells at 37°C for 5 d with M. leprae (+M. leprae) at concentrations ranging from 10 to 
250 ttg/ml, as indicated, or without M. leprae (-M. leprae). At the end of the incubation period, 
M. leprae, at the concentration indicated, was added to control cultures that had been incubated 
without it. The mononuclear cells from two replicate tissue culture wells were combined, 
distributed into three microtest wells, and assayed for capacity to incorporate [SH]thymidine, 
as described in Materials and Methods. Each point represents the mean cpm/microtest well 
for three replicate microtest wells _+ SEM. 
cell cultures  used  to  study  proliferative responses  to  Con  A  and M.  leprae  in 
Table III. 
Mononuclear cells from patients with both lepromatous and tuberculoid lep- 
rosy responded to Con A  with the generation of monocyte-activating cytokines, 
although  Con  A-induced supernatants  from patients  with  lepromatous leprosy 
were  less  potent  than  Con  A-induced  supernatants  from  the  patients  with 
tuberculoid  leprosy.  Supernatants  from  patients  with  lepromatous  leprosy re- 
sulted in a  mean  inhibition of 0.87  logs in L. pneumophila  multiplication while 
supernatants from patients with tuberculoid leprosy resulted in a mean inhibition 
of 1.61  logs. 
Mononuclear cells from patients with tuberculoid leprosy, with one exception, 
also responded to M. leprae antigens with the production of monocyte-activating 
cytokines.  M.  leprae  supernatants  generated  from  the  mononuclear  cells  of 
patients with tuberculoid leprosy resulted in a mean inhibition of 0.69 logs. This 
degree of inhibition  is comparable to that  resulting from treatment of normal 
monocytes with L. pneumophila-induced  supernatants generated from the mono- 
nuclear cells of patients recovered from Legionnaires' disease (13).  In contrast 
to mononuclear cells from patients with tuberculoid leprosy, mononuclear cells 
from patients  with  lepromatous leprosy failed to generate monocyte-activating 
cytokines  in  response  to M.  leprae.  In  fact,  in  three  of five cases,  monocytes 
treated with M.  leprae supernatants  showed  somewhat enhanced  multiplication 
of L.  pneumophila.  On  the  average, M.  leprae  supernatants  from patients  with 
lepromatous leprosy resulted in an enhancement of 0.13 logs. 
Thus,  the  capacity  of mononuclear  cells  from  patients  with  tuberculoid  or HORWITZ,  LEVIS,  AND  COHN  673 
TABLE  III 
[3H]Thymidine Incorporation  by Mononudear Cells of Patients with Leprosy in Response to Con 
A and M. teprae 
[3H]thymidine incorporation (cpm/microtest well) by mononuclear cells 
incubated with (4-) or without (-): 
Leprosy  Patient 
type  Con A  M. leprae 
4-  -  4-  - 
Lepromatous 
Tuberculoid 
A  12,486+527  220_+43  450±24  160±4 
C  12,119±87  357±42  682±177  851±311 
E  7,8t1±173  207--.10  1,112±38  207----.39 
F  5,197 ±  98  217 ±  24  3,116 ±  135  415 ±  30 
I  28,887+719  192±8  588±30  196±35 
J  25,363 ±  299  195 _+ 4  991 ±  34  226 ±  14 
M  5,271±714  166±13  1,303±29  211±9 
Mean13,876 ±  5520*  Mean  1,177 ±  524* 
D  12,437 ±  50  486 ±  153  27,588 ±  1203  640 ±  67 
G  12,497 +  308  203 ±  22  9,071 ±  297  314 ±  27 
H  11,683__.  556  259±4  4,636±  137  134+6 
K  15,971 ±  18  191 ±  6  20,443 ±  896  195 ±  29 
L  21,188±863  202±4  12,796±69  315+  13 
N  16,082±  157  --  12,402±672  190±  14 
Mean 14,976 ±  2069*  Mean14,489 ±  4766* 
Mononuclear cells (3 x  106/ml) were incubated in tissue culture wells at 37°C for 2 d with (+) or 
without (-) Con A (15 #g/ml) or for 5 d with or without M. leprae (100 #g/ml). At the end of the 
2 or 5 d incubation period, Con A or M. leprae was added to the appropriate control cultures that 
had been incubated without them. The monuclear cells from two tissue culture wells were combined, 
distributed into three microtest wells, and assayed for capacity to incorporate [SH]thymidine as 
described in  Materials and  Methods.  Each  pair of tissue culture  wells was  assayed in  triplicate 
microtest wells and the mean cpm/microtest well determined. Each datum on the table for patients 
A-J is the mean cpm/microtest well for the three microtest wells generated by one pair of tissue 
culture wells _+ SEM. Each datum on the table for patients K-N is the average of the mean cpm/ 
microtest well for three pairs of tissue culture wells (three microtest wells/pair) +  SEM. Patients 
were studied in six separate experiments as follows: Experiment 1, patient A; experiment 2, patients 
C  and D; experiment 3, patients E and F; experiment 4, patients G, H,  I, and J; experiment 5, 
patient K; experiment 6, patients L, M, and N. 
In separate experiments, mean [SH]thymidine incorporation in response to Con A by mononu- 
clear cells from seven normal persons was  11,939 _+_ 2,356, an amount not significantly different 
from that of mononuctear cells from patients with either form of leprosy. In experiment 1, [SH]- 
thymidine incorporation in response to M. leprae by mononuclear cells from a normal person with 
no history of mycobacterial disease was  196 ±  44; in the same experiment, [SH]thymidine incor- 
poration in response to M. leprae by a patient with lepromatous leprosy (patient A) was 450 ±  24 
and by a patient with tuberculoid leprosy (patient D) was 24,139 +  552. 
*P>  0.5. 
* P <  0.001. 
lepromatous leprosy to generate monocyte-activating cytokines generally paral- 
lels their capacity to incorporate thymidine in response to Con A and M. leprae. 
Discussion 
We  have  found  that  monocytes  from  patients  with  either  lepromatous  or 
tuberculoid leprosy can be activated normally, as measured by a highly relevant 
assay:  the capacity  of these  monocytes  to inhibit the multiplication  of another 674  DEFECTIVE  CYTOKINE  PRODUCTION  IN  LEPROMATOUS  LEPROSY 
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intracellular bacterial  pathogen, L. pneumophila.  Unless inhibition of M.  leprae 
multiplication requires a  qualitatively or quantitatively different form of activa- 
tion,  this suggests that  mononuclear phagocytes of patients  with  lepromatous 
and  tuberculoid  leprosy  have  the  capacity  to  control  M.  leprae  infection,  if 
activated. This finding therefore supports the hypothesis that the defect in cell- 
mediated immunity in  lepromatous  leprosy derives  from a  failure  to activate 
mononuclear phagocytes rather than from an intrinsic inability of these cells to 
be activated. This hypothesis does not exclude the possibility that mononuclear 
phagocytes located at  the site of infection are  somehow inhibited from being 
activated. 
Drutz et al. (19) previously reported that nonactivated human monocytes from 
patients with iepromatous and tuberculoid leprosy have comparable capacities to 
kill a  variety  of microorganisms (19)  Although mononuclear phatocytes must 
generally be activated to control infection by intracellular pathogens, this study 
by  Drutz  et  al.  further  supports the  hypothesis that  circulating  mononuclear 
phagocytes from patients with lepromatous leprosy have a normal antimicrobial 
capacity. 
We  have also found that mononuclear cells from patients with lepromatous 
and tuberculoid leprosy respond to Con A with [SH]thymidine incorporation and 
with the production of monocyte-activating cytokines whereas only mononuclear 
cells from patients with tuberculoid leprosy respond in these ways to M.  leprae. 
These  findings  suggest  that  mononuclear  cells  of patients  with  lepromatous 
leprosy have a  normal capacity to generate monocyte-activating cytokines but 
that they fail to do so in response to M.  leprae.  Alternatively, it is possible that 
mononuclear cells of patients with lepromatous leprosy, in response to M. leprae, 
generate substances inhibitory to monocyte activation at the same time as they 
generate monocyte-activating cytokines. However, this seems less likely in view 
of the fact that these mononuclear cells also fail to proliferate in response to M. 
leprae. These findings thus support the hypothesis that the defect in cell-mediated 
immunity in patients with lepromatous leprosy derives from a failure to generate, 
in response to M.  leprae  but not other antigens, cytokines necessary to activate 
mononuclear phagocytes. If this is so, then the underlying basis for this profound 
defect in  cytokine production is obscure,  although suppressor cells or  factors 
have  been  suggested as  playing a  role  (20,  21).  Consistent  with a  suppressor 
mechanism, Van Voorhis et al. (22) have recently reported from this laboratory 
that the T  cell population in skin lesions of patients with lepromatous leprosy is 
devoid of OKT4/Leu  3a-positive (helper) cells and is comprised almost exclu- 
sively of OKT8/Leu  2a-positive (suppressor) cells. In contrast, the T  cell popu- 
lation in skin lesions of patients with tuberculoid leprosy is comprised predomi- 
nantly of OKT4/Leu  3a-positive cells  (22).  Similarly,  Modlin  et al.  (23)  have 
reported that the T  cell helper/suppressor ratio in two patients with uncompli- 
cated  lepromatous  leprosy  was  lower  than  in  four  patients  with  tuberculoid 
leprosy.  More recent studies indicate that peripheral  blood mononuclear cells 
from patients with lepromatous leprosy fail to produce interleukin 2 or gamma 
interferon in response to M. leprae. 676  DEFECTIVE  CYTOKINE  PRODUCTION  IN  LEPROMATOUS  LEPROSY 
Summary 
We have examined the capacity of monocytes from patients with leprosy to 
undergo activation and the capacity of mononuclear cells from these patients to 
incorporate [3H]thymidine and produce monocyte-activating cytokines. 
Monocytes from patients with either lepromatous or tuberculoid leprosy were 
activated by  concanavalin  A  (Con  A)-induced mononuclear cell  supernatants 
generated from the leukocytes of a normal person. Monocytes activated by these 
supernatants strongly inhibited L. pneumophila multiplication, and the degree of 
inhibition was comparable in both groups of patients. 
Mononuclear cells from patients with either form of leprosy responded com- 
parably to Con A with vigorous [~H]thymidine incorporation. Mononuclear cells 
from patients with tuberculoid leprosy also vigorously incorporated [3H]thymi- 
dine  in  response  to  M.  Ieprae  antigens.  In  contrast,  mononuclear cells  from 
patients  with  lepromatous  leprosy  did  not  exhibit  significant  [3H]thymidine 
incorporation in response to M. leprae antigens. 
The capacity of mononuclear cells to generate monocyte-activating cytokines 
generally paralleled their capacity to incorporate [3H]thymidine in response to 
Con A and M. leprae. Mononuclear cells from patients with either form of leprosy 
responded  to  Con  A  with  the production  of cytokines (supernatants) able  to 
activate normal monocytes, expressed by inhibition of L. pneumophila  multipli- 
cation.  However Con A-induced supernatants from patients with lepromatous 
leprosy were less potent than Con A-induced supernatants from patients with 
tuberculoid leprosy. Mononuclear cells from patients with tuberculoid leprosy 
responded to M. leprae antigens with the production of potent monocyte-activat- 
ing supernatants. In contrast, mononuclear cells from patients with lepromatous 
leprosy did not produce monocyte-activating cytokines in response to M.  leprae 
antigens. 
These studies support the hypothesis that the immunological defect in lepro- 
matous leprosy results from a failure to activate mononuclear phagocytes rather 
than from an intrinsic inability of these cells to be activated. We suggest that the 
failure to activate mononuclear phagocytes stems from defective production of 
monocyte-activating cytokines in response to M. leprae antigens. 
We  are grateful to  Ms.  Barbara  Jane  Fink and  Ms.  Diane  Chodkowski for excellent 
technical assistance. We also thank the Rockefeller University Hospital Clinic Staff for 
their invaluable assistance. 
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